n | Exitus | Mean ± Standard Error (95% Confidence Interval) | 5-year survival (%) | p | |
---|---|---|---|---|---|
Overall survival | 72 | 24 | 81.54 ± 7.01 (67.80–95.29) | 56.5 ± 7.4 | N/A |
Age | |||||
< 60 | 28 | 7 | 58.30 ± 5.45 (47.63–68.98) | 56.4 ± 14.2 | 0.295 |
≥ 60 | 44 | 17 | 77.69 ± 8.80 (60.45–94.93) | 55.1 ± 8.6 | |
Sex | |||||
Male | 39 | 13 | 83.22 ± 9.17 (65.25–101.19) | 59.0 ± 9.2 | 0.878 |
Female | 33 | 11 | 75.77 ± 10.42 (55.34–96.19) | 52.0 ± 12.2 | |
Comorbidity | |||||
No | 26 | 7 | 83.75 ± 12.80 (58.67–108.84) | 54.2 ± 15.5 | 0.374 |
Yes | 46 | 17 | 71.59 ± 7.70 (56.49–86.69) | 55.1 ± 8.5 | |
Type | |||||
Heavy chain | 58 | 23 | 75.08 ± 7.72 (59.94–90.21) | 50.4 ± 7.9 | 0.051 |
Light chain | 14 | 1 | 70.36 ± 4.47 (61.59–79.13) | 92.9 ± 6.9 | |
Stage | |||||
Others | 19 | 1 | 117.77 ± 6.95 (104.15–131.39) | 92.3 ± 7.4 | 0.003 |
Stage III (A/B) | 47 | 22 | 62.21 ± 7.53 (47.46–76.96) | 42.6 ± 8.8 | |
Lytic lesion | |||||
No | 19 | 7 | 49.68 ± 7.80 (34.39–64.97) | 58.3 ± 12.6 | 0.861 |
Yes | 33 | 16 | 52.19 ± 6.24 (39.96–64.42) | 41.3 ± 10.2 | |
Plasmacytoma | |||||
No | 48 | 16 | 79.97 ± 8.91 (62.50–97.44) | 56.7 ± 8.9 | 0.683 |
Yes | 22 | 8 | 75.75 ± 10.32 (55.53–95.98) | 53.8 ± 13.5 | |
Hypercalcemia | |||||
No | 59 | 17 | 86.87 ± 7.65 (71.88–101.86) | 62.3 ± 8.0 | 0.023 |
Yes | 9 | 6 | 32.94 ± 7.90 (17.46–48.43) | 19.4 ± 16.2 | |
High creatinine (> 2) | |||||
No | 53 | 14 | 89.86 ± 7.89 (74.39–105.33) | 64.4 ± 8.5 | 0.012 |
Yes | 18 | 10 | 39.07 ± 7.18 (25.00–53.13) | 28.7 ± 14.5 | |
Bone marrow fibrosis level | |||||
0 | 15 | 4 | 85.27 ± 11.77 (62.20–108.34) | 70.9 ± 12.4 | 0.730 |
1–4 | 55 | 18 | 82.66 ± 7.96 (67.07–98.26) | 58.0 ± 8.3 | |
Response to treatment (primary line) | |||||
Others | 25 | 12 | 48.45 ± 7.64 (33.47–63.43) | 34.7 ± 13.6 | 0.003 |
VGPR & CR | 33 | 5 | 105.31 ± 7.92 (89.79–120.82) | 78.5 ± 8.8 | |
Autologous stem cell transplantation | |||||
No | 36 | 16 | 48.98 ± 6.90 (35.45–62.51) | 42.2 ± 11.1 | 0.007 |
Yes | 35 | 7 | 99.64 ± 8.35 (83.28–116.01) | 73.6 ± 8.8 |